Skip to main content

Advertisement

SpringerLink
Log in

Prostate cancer post-treatment follow-up and recurrence evaluation

  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Recurrent prostate cancer following primary treatment is common, and the population of men with biochemical recurrence is complex. Conventional management of recurrent prostate cancer involves nontargeted and/or systemic therapies, without defining an individual patient’s specific disease. However, recent advances in imaging enable a shift in the management of recurrent prostate cancer to targeted, patient-specific approaches. Specifically, MRI can detect and define local prostate cancer recurrence early in the course of disease, and prostate-specific PET imaging greatly improves nodal staging and can detect previously unknown distant metastases. The significant advances in the imaging of both local and distant tumor recurrences allows for specific selection of treatment options tailored to patients and their disease with less associated morbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30

    Article  PubMed  Google Scholar 

  2. Cookson MS, Aus G, Burnett AL, et al. (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177(2):540–545

    Article  CAS  PubMed  Google Scholar 

  3. Freedland SJ, Humphreys EB, Mangold LA, et al. (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439

    Article  CAS  PubMed  Google Scholar 

  4. Stephenson AJ, Kattan MW, Eastham JA, et al. (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24(24):3973–3978

    Article  CAS  PubMed  Google Scholar 

  5. Pound CR, Partin AW, Eisenberger MA, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597

    Article  CAS  PubMed  Google Scholar 

  6. Mohler JL, Kantoff PW, Armstrong AJ, et al. (2014) Prostate cancer, version 2.2014. J Natl Compr Cancer Netw 12(5):686–718

    CAS  Google Scholar 

  7. Mitchell CR, Lowe VJ, Rangel LJ, et al. (2013) Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol 189(4):1308–1313

    Article  PubMed  Google Scholar 

  8. Kitajima K, Murphy RC, Nathan MA, et al. (2014) Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med 55(2):223–232

    Article  CAS  PubMed  Google Scholar 

  9. Partin AW, Pearson JD, Landis PK, et al. (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43(5):649–659

    Article  CAS  PubMed  Google Scholar 

  10. Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Saigal CS, Gore JL, Krupski TL, et al. (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110(7):1493–1500

    Article  CAS  PubMed  Google Scholar 

  12. Crawford ED, Moul JW (2015) ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Oncology (Williston Park) 29(1):55–58, 65–56

    Google Scholar 

  13. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV (2009) Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302(8):866–873

    Article  CAS  PubMed  Google Scholar 

  14. Heidenreich A, Bastian PJ, Bellmunt J, et al. (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479

    Article  CAS  PubMed  Google Scholar 

  15. Stephenson AJ, Scardino PT, Kattan MW, et al. (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041

    Article  PubMed  PubMed Central  Google Scholar 

  16. Uddin Ahmed H, Cathcart P, Chalasani V, et al. (2012) Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. Cancer 118(12):3071–3078

    Article  PubMed  Google Scholar 

  17. Ehdaie B, Atoria CL, Gupta A, et al. (2012) Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer 118(13):3397–3406

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164

    Article  CAS  PubMed  Google Scholar 

  19. Saylor PJ, Smith MR (2013) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 189(1):S34–42 (Discussion S43–34)

    Article  CAS  PubMed  Google Scholar 

  20. Woodrum DA, Kawashima A, Karnes RJ, et al. (2013) Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience. Urology 82(4):870–875

    Article  PubMed  Google Scholar 

  21. Trock BJ, Han M, Freedland SJ, et al. (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299(23):2760–2769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Karnes RJ, Murphy CR, Bergstralh EJ, et al. (2015) Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol 193(1):111–116

    Article  PubMed  Google Scholar 

  23. Thompson IM, Valicenti RK, Albertsen P, et al. (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 190(2):441–449

    Article  PubMed  Google Scholar 

  24. American College of Radiology (1996) ACR appropriateness criteria: post-treatment follow-up of prostate cancer. Vol origin 1996. Last reviewed 2011

  25. Krause BJ, Souvatzoglou M, Tuncel M, et al. (2008) The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35(1):18–23

    Article  CAS  PubMed  Google Scholar 

  26. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47(2):225–231

    Article  CAS  PubMed  Google Scholar 

  27. Linder BJ, Kawashima A, Woodrum DA, et al. (2014) Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging. Can J Urol 21(3):7283–7289

    PubMed  Google Scholar 

  28. Kane CJ, Amling CL, Johnstone PA, et al. (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61(3):607–611

    Article  PubMed  Google Scholar 

  29. Kramer S, Gorich J, Gottfried HW, et al. (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70(838):995–999

    Article  CAS  PubMed  Google Scholar 

  30. National Comprehensive Cancer Network (2015) NCCN clinical practice guidelines in oncology (NCCN guideline): prostate cancer. Version 1.2015 ed

  31. Jadvar H, Desai B, Ji L, et al. (2012) Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med 37(7):637–643

    Article  PubMed  PubMed Central  Google Scholar 

  32. Meijer HJ, Debats OA, van Lin EN, et al. (2013) A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured. Radiat Oncol 8:190

    Article  PubMed  PubMed Central  Google Scholar 

  33. Fortuin AS, Smeenk RJ, Meijer HJ, Witjes AJ, Barentsz JO (2014) Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential. Curr Urol Rep 15(3):389

    Article  PubMed  Google Scholar 

  34. Pasoglou V, Michoux N, Peeters F, et al. (2015) Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 275(1):155–166

    Article  PubMed  Google Scholar 

  35. Wasserman NF, Kapoor DA, Hildebrandt WC, et al. (1992) Transrectal US in evaluation of patients after radical prostatectomy. Part I. Normal postoperative anatomy. Radiology 185(2):361–366

    Article  CAS  PubMed  Google Scholar 

  36. Allen SD, Thompson A, Sohaib SA (2008) The normal post-surgical anatomy of the male pelvis following radical prostatectomy as assessed by magnetic resonance imaging. Eur Radiol 18(6):1281–1291

    Article  PubMed  Google Scholar 

  37. Casciani E, Polettini E, Carmenini E, et al. (2008) Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 190(5):1187–1192

    Article  PubMed  Google Scholar 

  38. Wassberg C, Akin O, Vargas HA, et al. (2012) The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol 199(2):360–366

    Article  PubMed  PubMed Central  Google Scholar 

  39. Cirillo S, Petracchini M, Scotti L, et al. (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19(3):761–769

    Article  PubMed  Google Scholar 

  40. Roy C, Foudi F, Charton J, et al. (2013) Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. AJR Am J Roentgenol 200(4):W361–W368

    Article  PubMed  Google Scholar 

  41. Rischke HC, Schafer AO, Nestle U, et al. (2012) Detection of local recurrent prostate cancer after radical prostatectomy in terms of salvage radiotherapy using dynamic contrast enhanced-MRI without endorectal coil. Radiat Oncol 7:185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Haider MA, Chung P, Sweet J, et al. (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70(2):425–430

    Article  PubMed  Google Scholar 

  43. Morgan VA, Riches SF, Giles S, Dearnaley D, deSouza NM (2012) Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol 198(3):596–602

    Article  PubMed  Google Scholar 

  44. Fortuin AS, Deserno WM, Meijer HJ, et al. (2012) Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases. Int J Radiat Oncol Biol Phys 84(3):712–718

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA

    Eric J. May, Lyndsay D. Viers, Akira Kawashima & Adam T. Froemming

  2. Department of Urology, Mayo Clinic, Rochester, MN, USA

    Boyd R. Viers, Eugene D. Kwon & R. Jeffrey Karnes

Authors
  1. Eric J. May
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lyndsay D. Viers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boyd R. Viers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akira Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eugene D. Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Jeffrey Karnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Adam T. Froemming
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric J. May.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

May, E.J., Viers, L.D., Viers, B.R. et al. Prostate cancer post-treatment follow-up and recurrence evaluation. Abdom Radiol 41, 862–876 (2016). https://doi.org/10.1007/s00261-015-0562-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-015-0562-1

Keywords

Search

Navigation